Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
CONCLUSIONS: HoFH is a severe life threating disease with a high genetic and phenotypic variability. The improvement in lipid-lowering treatment and LDL-C levels have contributed to reduce ASCVD events.PMID:38523000 | DOI:10.1016/j.atherosclerosis.2024.117516 (Source: Atherosclerosis)
Source: Atherosclerosis - March 24, 2024 Category: Cardiology Authors: Rodrigo Alonso Raquel Arroyo-Olivares Jose Luis D íaz-Díaz Francisco Fuentes-Jim énez Francisco Arrieta Raimundo de Andr és Pablo Gonzalez-Bustos Rosa Argueso Mercedes Martin-Ordiales Ceferino Martinez-Faedo F átima Illán Pedro Saenz Jos é María D Source Type: research
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research
The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction
This study aimed to investigate the impact of the latest guidelines on the real-world clinical practice of initial lipid-lowering therapy, especially on the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in China. All adult patients diagnosed with acute myocardial infarction in our hospital between August 31, 2018, and August 31, 2020, were divided into the following 2 groups: those patients treated before the latest guideline release, and those patients treated after the release. A propensity score-matched method was used, and logistic regression was used to assess the association wi...
Source: Atherosclerosis - March 22, 2024 Category: Cardiology Authors: Xiangqi Kong Gang He Xiaoqing Quan Zhixiong Tan Fengjuan Yan Xiehui Chen Source Type: research
The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction
This study aimed to investigate the impact of the latest guidelines on the real-world clinical practice of initial lipid-lowering therapy, especially on the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in China. All adult patients diagnosed with acute myocardial infarction in our hospital between August 31, 2018, and August 31, 2020, were divided into the following 2 groups: those patients treated before the latest guideline release, and those patients treated after the release. A propensity score-matched method was used, and logistic regression was used to assess the association wi...
Source: Atherosclerosis - March 22, 2024 Category: Cardiology Authors: Xiangqi Kong Gang He Xiaoqing Quan Zhixiong Tan Fengjuan Yan Xiehui Chen Source Type: research
Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
ConclusionsWe observed a reduction in senescent CD8+ T cells and an increase in the ratio of naive to memory CD8+ T cells with rosuvastatin/ezetimibe treatment. Our results demonstrate the immunomodulatory roles of ezetimibe in combination with statins, independent of improvements in lipid or HbA1c levels. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 22, 2024 Category: Endocrinology Source Type: research
